Clinical Trial Update: Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2) [Phase 2]

View source ↗

Summary

Phase 2 trial update for MUSE 2 maximal use systemic exposure study of Levulan Kerastick (ALA-based PDT) completed in actinic keratosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Keratosis Actinic

Drugs mentioned

• LEVULAN KERASTICK (AMINOLEVULINIC ACID HYDROCHLORIDE)

Snippet

Sponsor: DUSA Pharmaceuticals, Inc. | Conditions: Keratosis, Actinic | Phase 2 | Status: COMPLETED | Results posted: 2017-09-18